- Home
- NVGS vs MLTX Comparison
NVGS vs MLTX Comparison
Compare NVGS & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVGS | MLTX |
|---|---|---|
| Founded | 1997 | 2021 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NVGS | MLTX |
|---|---|---|
| Price | $20.93 | $20.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $21.50 | ★ $27.50 |
| AVG Volume (30 Days) | 472.4K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.08 | $5.95 |
| 52 Week High | $24.36 | $62.75 |
Technical Indicators
Market Signals| Indicator | NVGS | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 56.33 |
| Support Level | $17.38 | $15.89 |
| Resistance Level | $21.36 | $21.00 |
| Average True Range (ATR) | 0.83 | 0.85 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 68.15 | 56.74 |
Price Performance
Historical ComparisonAbout NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.